Literature DB >> 1321654

Effects of granisetron and haloperidol, alone and in combination, on psychometric performance and the EEG.

T J Leigh1, C G Link, G L Fell.   

Abstract

1. The effects of granisetron (160 micrograms kg-1 body weight) and haloperidol (3 mg) on psychometric performance and the EEG were investigated in a randomised, single-blind, crossover, placebo controlled study of 12 healthy male volunteers. 2. There was evidence that haloperidol impaired psychometric performance; however its effects on the EEG were not clear cut. In contrast there was very little evidence to suggest that granisetron had any impact on performance or the EEG. 3. The findings from this study suggest that granisetron does not impair daytime function and that it can be co-administered with haloperidol without producing unwanted synergistic effects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1321654      PMCID: PMC1381377          DOI: 10.1111/j.1365-2125.1992.tb04109.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Effects of granisetron and lorazepam, alone and in combination, on psychometric performance.

Authors:  T J Leigh; C G Link; G L Fell
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

2.  Effects of granisetron and lorazepam, alone and in combination, on the EEG of human volunteers.

Authors:  C G Link; T J Leigh; G L Fell
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 3.  Neuropharmacology of emesis induced by anti-cancer therapy.

Authors:  P L Andrews; W G Rapeport; G J Sanger
Journal:  Trends Pharmacol Sci       Date:  1988-09       Impact factor: 14.819

4.  Identification of 5-HT3 recognition sites in human brain tissue using [3H]zacopride.

Authors:  N M Barnes; B Costall; J W Ironside; R J Naylor
Journal:  J Pharm Pharmacol       Date:  1988-09       Impact factor: 3.765

5.  Spectral difference index: a single EEG measure of drug effect.

Authors:  P Irwin
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1982-09

6.  The effects of haloperidol on the EEG spectrum.

Authors:  G H Wieneke; W M Verhoeven; H G Westenberg; H de Wilde; F H Lopes da Silva; M van Praag; W Storm van Leeuwen
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

7.  Cimetidine, metoclopramide, or placebo in the treatment of symptomatic gastroesophageal reflux.

Authors:  P Bright-Asare; M El-Bassoussi
Journal:  J Clin Gastroenterol       Date:  1980-06       Impact factor: 3.062

8.  Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group.

Authors:  B Chevallier
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

9.  Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis.

Authors:  W D Miner; G J Sanger; D H Turner
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640

  9 in total
  3 in total

Review 1.  Biomarkers for the effects of antipsychotic drugs in healthy volunteers.

Authors:  S J de Visser; J van der Post; M S Pieters; A F Cohen; J M van Gerven
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

2.  Electroencephalographic and psychomotor effects of chlorpromazine and risperidone relative to placebo in normal healthy volunteers.

Authors:  A M Hughes; P Lynch; J Rhodes; C M Ervine; R A Yates
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

Review 3.  Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy.

Authors:  Y E Yarker; D McTavish
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.